Jeremiah Pharms was on track for exclusive rights restricted free agency this offseason. Instead, he will be remaining with the Patriots. 
The former undrafted defensive lineman has agreed to a two-year deal with New England, his agency announced. ESPN’s Mike Reiss notes the pact is expected to included a $100K signing bonus and $250K in overall guarantees. If he remains on the roster through next season, restricted free agency in 2026 will be avoided.
Pharms signed to the Patriots’ practice squad following roster cutdowns in 2022. He did not see any playing time that season, but he remained in the organization via a futures contract. The 28-year-old wound up making 12 appearances in 2023, handing rotational duties along the D-line. This past season, Pharms took on a much larger role.
With Christian Barmore being limited to four games in 2024, plenty of opportunities existed for players further down the depth chart to see playing time in New England. That allowed Pharms to log a 40% snap share, and his increased workload resulted in a spike in production (33 tackles, two sacks, five quarterback hits). He could again find himself handling a notable part-time defensive role with the Patriots next season.
New England is currently set to select fourth in this year’s draft, and addressing the offensive line is a goal which could be achieved in large part by using that pick to provide better protection for quarterback Drake Maye. Another option near the top of the board would be to add one of the many highly-touted defensive linemen in the 2025 class, something which could threaten Pharms’ playing time. For the time being, though, he is set to remain a rotational contributor with the Patriots.